Theravance Biopharma to Sell TRELEGY ELLIPTA Royalty Interests to Royalty Pharma for Approximately $1.1 Billion in Upfront Cash with Over $1.5 Billion in Potential Total Value

Over $1.5 Billion in Potential Total Value, Including Approximately $1.1 Billion in Upfront Cash, up to $250 Million in Sales-Based Milestone Payments and an...

Related Keywords

Germany ,Italy ,Dublin ,Ireland ,France ,Spain ,Ricke Winningham ,Pablo Legorreta ,Theravance Biopharma ,Gail Cohen ,Exchange For Unsecured Low Single ,Theravance Biopharma Inc ,Drug Administration ,Meagher Flom ,Theravance Respiratory Company ,Corporate Communications ,Prnewswire Theravance Biopharma Inc ,European Medicines Agency ,Securities Exchange ,Viatris Company ,Goodwin Procter ,Million To Advance Development Of Ampreloxetine ,Potential Total Value ,Including Approximately ,Upfront Cash ,Sales Based Milestone Payments ,Advance Development ,Multiple System Atrophy ,Unsecured Low Single Digit Royalties ,Conference Call Today ,Royalty Pharma ,Senior Notes ,Chief Executive ,Chief Executive Officer ,New Drug Application ,Live Webcast Today ,Private Securities Litigation Reform Act ,Securities Exchange Act ,Convertible Senior Notes Due ,Tender Offer Statement ,Tender Offer ,